Responses
Clinical science
Original article
Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up
Compose a Response to This Article
Other responses
No responses have been published for this article.